Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-183: Pembrolizumab + Pomalidomide + Dexamethasone in rrMM
NCT02576977Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2015
- Primary completion
- Jul 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in multiple myeloma (MM) (2 arms), sponsored by Merck & Co. Primary endpoints: Progression-Free Survival at 30 months and Overall Survival at 54 months. Started Oct 2015; status: terminated.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02576977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576977.